You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物-B(02197.HK)夥科園貿易合作 料下半年商業化內地上市銷售四價季節性流感疫苗
阿思達克 05-24 08:48
三葉草生物-B(02197.HK)公布,與科園貿易建立商業合作夥伴關係,科園貿易是中國領先的醫藥進口及分銷企業,為AdimFluS(QIS)的商業上市做準備,該款疫苗是內地目前唯一獲批用於三歲及以上人群的進口四價季節性流感疫苗。公司預計今年下半年商業化上市銷售AdimFluS(QIS)。 公司指出,與科園貿易的合作將支持公司落地其季節性流感疫苗AdimFlu-S(QIS)的商業戰略。科園貿易廣泛的分銷網絡遍布全國31個省、直轄市及自治區,覆蓋2,000多家區縣疾病預防控制中心。科園貿易將補充公司已建立和不斷增長的商業能力,最大化其在中國各地的可及性。 此外,公司料AdimFlu-S(QIS)的銷售額將增加其今年的收入,並為明年及以後的增長做出有意義的貢獻。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account